GlassScriptPhysician profile
Paul Faik Hanona
NPI 1992366686
$2,198.07
in general payments reported to CMS, 2019-2025
18 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $466 · 2023: $437 · 2024: $1,073 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $648.80 | 2022-2025 | Blincyto, Kyprolis, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $421.40 | 2024-2025 | Opdivo, Opdualag, Augtyro |
| Genzyme Corporation | $260.85 | 2022-2025 | |
| Pharmaessentia USA Corporation | $140.57 | 2022-2023 | Besremi |
| Gilead Sciences, INC. | $124.74 | 2023 | Trodelvy |
| Eisai INC. | $78.95 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $77.25 | 2024 | Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $75.45 | 2023-2025 | Iclusig, Fruzaqla |
| Merck Sharp & Dohme LLC | $71.12 | 2022-2024 | Keytruda |
| Genmab U.S., INC. | $52.73 | 2024-2025 | Epkinly |
| Genentech USA, INC. | $46.93 | 2023-2024 | Alecensa, Tecentriq, Polivy |
| Beigene USA, INC. | $44.67 | 2022-2024 | Brukinsa |
| Celgene Corporation | $34.97 | 2023 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $34.38 | 2024 | Libtayo |
| Janssen Biotech, INC. | $27.69 | 2025 | Rybrevant |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $22.37 | 2022 | |
| Incyte Corporation | $19.13 | 2023 | Jakafi |
| Servier Pharmaceuticals LLC | $16.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hanona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.